Parkinson's disease medical therapy: Difference between revisions
Jump to navigation
Jump to search
(Replaced content with "__NOTOC__ {{Parkinson's disease}} {{CMG}} ==Overview== ==Medical Therapy== ==References== {{Reflist|2}} {{WH}} {{WS}}") |
|||
Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
The mainstay of therapy for motor symptoms of Parkinson disease are: | |||
* Levodopa: | |||
* Dopamine agonists: | |||
* Monoamine oxidase (MAO) B inhibitors: | |||
* Anticholinergic agents: | |||
* Amantadine: | |||
* Catechol-O-methyl transferase (COMT) inhibitors: | |||
==References== | ==References== |
Revision as of 06:21, 19 April 2018
Parkinson's disease Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Parkinson's disease medical therapy On the Web |
American Roentgen Ray Society Images of Parkinson's disease medical therapy |
Risk calculators and risk factors for Parkinson's disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
The mainstay of therapy for motor symptoms of Parkinson disease are:
- Levodopa:
- Dopamine agonists:
- Monoamine oxidase (MAO) B inhibitors:
- Anticholinergic agents:
- Amantadine:
- Catechol-O-methyl transferase (COMT) inhibitors: